Identification | Back Directory | [Name]
Tocainide hydrochloride | [CAS]
35891-93-1 | [Synonyms]
Xylotocan TOCAINIDE HCL Unii-2K7I38ckn5 tonocardhydrochloride tocainide hydrochloride TOCAINIDE HYDROCHLORIDE (125 MG) Tocainide hydrochloride USP/EP/BP 2-amino-n-(2,6-dimethylphenyl)propanamide hydrochloride 2-amino-n-(2,6-dimethylphenyl)propanamidemonohydrochloride 2-amino-n-(2,6-dimethylphenyl)-propanamidmonohydrochloride Propanamide, 2-amino-N-(2,6-dimethylphenyl)-, monohydrochloride | [Molecular Formula]
C11H17ClN2O | [MDL Number]
MFCD00941502 | [MOL File]
35891-93-1.mol | [Molecular Weight]
228.718 |
Chemical Properties | Back Directory | [Melting point ]
244-245°C | [storage temp. ]
-20°C Freezer | [solubility ]
Methanol (Slightly), Water (Slightly) | [form ]
Solid | [color ]
Off-White |
Hazard Information | Back Directory | [Uses]
Tonocard(AstraZeneca). | [General Description]
Tocainide hydrochloride,2-amino-2' ,6 '-propionoxyxylidide hydrochloride (Tonocard)(pKa 7.7), is an analog of lidocaine. It is orally active and haselectrophysiological properties like those of lidocaine. Totalbody clearance of tocainide hydrochloride is only166 mL/min, suggesting that hepatic clearance is not large.Because of low hepatic clearance, the hepatic extraction ratiomust be small; therefore, tocainide hydrochloride is unlikelyto be subject to a substantial first-pass effect. The drug differsfrom lidocaine, in that it lacks two ethyl groups, which providestocainide hydrochloride some protection from first-passhepatic elimination after oral ingestion. Tocainide hydrochlorideis hydrolyzed in a manner similar to that of lidocaine.None of its metabolites is active. | [Clinical Use]
Tocainide hydrochloride is classed as a IB antiarrhythmicagent and used orally to prevent or treat ventricular ectopyand tachycardia. The drug is given in 400- to 600-mgdoses every 8 hours. | [Veterinary Drugs and Treatments]
Veterinary experience with tocainide is limited. At this time, dogs
are the only veterinary species where enough clinical experience has
been garnered to recommend its use. It is indicated for the oral therapy
of ventricular arrhythmias, principally ventricular tachycardia
and ventricular premature complexes. In humans, response to lidocaine
can usually predict whether tocainide might be effective. |
|
Company Name: |
Boen pharm
|
Tel: |
86 512-62572107 62962707 |
Website: |
www.is0513.com/ShowSupplierProductsList19300/0.htm |
Company Name: |
InvivoChem
|
Tel: |
13549236410 |
Website: |
https://www.invivochem.cn/ |
|